ALZN Fundamental Analysis - ALZAMEND NEURO INC

Fundamental Rating

Overall ALZN gets a fundamental rating of 2 out of 10. We evaluated ALZN against 547 industry peers in the Biotechnology industry. While ALZN seems to be doing ok healthwise, there are quite some concerns on its profitability. ALZN is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ALZN has reported negative net income.

In the past year ALZN has reported a negative cash flow from operations.

In the past 5 years ALZN always reported negative net income.

In the past 5 years ALZN always reported negative operating cash flow.

1.2 Ratios

ALZN has a worse Return On Assets (-112.07%) than 77.70% of its industry peers.

ALZN has a Return On Equity (-130.00%) which is in line with its industry peers.

		Industry Rank	Sector Rank
ROA	-112.07%
ROE	-130%
ROIC	N/A

ROA(3y)-645.75%

ROA(5y)-439.18%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALZN so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALZN has more shares outstanding than it did 1 year ago.

ALZN has more shares outstanding than it did 5 years ago.

ALZN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

ALZN has an Altman-Z score of -12.86. This is a bad value and indicates that ALZN is not financially healthy and even has some risk of bankruptcy.

ALZN has a worse Altman-Z score (-12.86) than 77.15% of its industry peers.

There is no outstanding debt for ALZN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-12.86

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

ALZN has a Current Ratio of 6.58. This indicates that ALZN is financially healthy and has no problem in meeting its short term obligations.

With a decent Current ratio value of 6.58, ALZN is doing good in the industry, outperforming 65.45% of the companies in the same industry.

ALZN has a Quick Ratio of 6.58. This indicates that ALZN is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of ALZN (6.58) is better than 66.18% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	6.58
Quick Ratio	6.58

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ALZN have decreased strongly by -22.44% in the last year.

EPS 1Y (TTM)-22.44%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%78.15%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.79% on average over the next years. This is quite good.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y94.04%

EPS Next 2Y40.71%

EPS Next 3Y25.55%

EPS Next 5Y14.79%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALZN. In the last year negative earnings were reported.

Also next year ALZN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ALZN's earnings are expected to grow with 25.55% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y40.71%

EPS Next 3Y25.55%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ALZN!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ALZAMEND NEURO INC

NASDAQ:ALZN (8/27/2025, 11:01:57 AM)

2.41

-0.03 (-1.23%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)07-22 2025-07-22/bmo

Earnings (Next)09-09 2025-09-09

Inst Owners0.21%

Inst Owner Change-72.03%

Ins Owners0.88%

Ins Owner Change8.14%

Market Cap7.57M

Analysts80

Price Target45.9 (1804.56%)

Short Float %5.57%

Short Ratio0.56

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-75%

PT rev (3m)125%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-800%

EPS NY rev (1m)55.51%

EPS NY rev (3m)55.51%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	1.91
P/tB	1.91
EV/EBITDA	N/A

EPS(TTM)-247.95

EYN/A

EPS(NY)-4.98

Fwd EYN/A

FCF(TTM)-2.19

FCFYN/A

OCF(TTM)-2.09

OCFYN/A

SpS0

BVpS1.26

TBVpS1.26

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-112.07%
ROE	-130%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-645.75%

ROA(5y)-439.18%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	591.72%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	6.58
Quick Ratio	6.58
Altman-Z	-12.86

F-Score5

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)294.02%

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-22.44%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%78.15%

EPS Next Y94.04%

EPS Next 2Y40.71%

EPS Next 3Y25.55%

EPS Next 5Y14.79%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y54.77%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-114.91%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y18.4%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y20.58%

OCF growth 3YN/A

OCF growth 5YN/A

ALZAMEND NEURO INC (ALZN) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens